Leerink Partnrs Estimates REGENXBIO FY2029 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of REGENXBIO in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar forecasts that the biotechnology company will post earnings per share of $0.46 for the year. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.87) per share.

RGNX has been the topic of a number of other research reports. Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. Raymond James reiterated an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of REGENXBIO in a report on Wednesday, January 15th. Morgan Stanley reissued an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus target price of $34.82.

REGENXBIO Price Performance

RGNX stock traded down $0.28 during trading on Thursday, reaching $7.57. 41,630 shares of the company were exchanged, compared to its average volume of 1,250,393. The company has a market capitalization of $375.02 million, a price-to-earnings ratio of -1.50 and a beta of 1.28. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The company has a 50-day moving average of $8.52 and a two-hundred day moving average of $10.42.

Institutional Trading of REGENXBIO

Hedge funds have recently modified their holdings of the business. Amalgamated Bank boosted its stake in REGENXBIO by 9.9% in the 2nd quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 1,227 shares in the last quarter. FMR LLC grew its holdings in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,656 shares during the period. nVerses Capital LLC boosted its position in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 2,200 shares during the last quarter. GAMMA Investing LLC increased its position in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of REGENXBIO by 19.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,375 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 3,015 shares during the period. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.